Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 386

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 8
Chunk 386
---
/or the pursuit of strategic partnerships, licensing arrangements or collaborations to fund our future operations and remain as a going concern. To the extent that we raise additional capital through future equity offerings, the ownership interest of common stockholders will be diluted, which may be significant. See "Note 1 - Organization and Nature of Business" to our unaudited interim condensed consolidated financial statements in this Quarterly Report on Form 10-Q for additional information on our assessment. Until such time as we can generate revenue from product sales, if ever, we expect to finance our cash needs through a combination of equity offerings, debt financings, and potential collaborations, license and development agreements.

29

Cash Flows

The following table summarizes our sources and uses of cash for the periods indicated:

Three Months Ended March 31,20252024(in thousands)Net cash (used in) provided by:Operating activities$(14,081)$(15,491)Investing activities(9)21,393 Financing activities13,811 980 Net (decrease) increase in cash and cash equivalents$(279)$6,882 

Net Cash Used in Operating Activities

During the three months ended March 31, 2025, operating activities used approximately $14.1 million of cash, primarily resulting from our net loss of approximately $15.0 million and changes in assets and liabilities of $1.0 million, partially offset by stock-based compensation expense of approximately $1.7 million and the reduction in carrying amount of right-of-use assets of approximately $0.1 million.

During the three months ended March 31, 2024, operating activities used approximately $15.5 million of cash, primarily resulting from our net loss of approximately $14.3 million and changes in assets and liabilities of $2.7 million, partially offset by stock-based compensation expense of approximately $1.5 million and the reduction in carrying amount of right-of-use assets of approximately $0.1 million.

Net Cash (Used in) Provided by Investing Activities

During the three months ended March 31, 2025, investing activities used approximately $9 thousand of cash, primarily resulting from purchases of property and equipment of approximately $9 thousand. 

During the three months ended March 31, 2024, investing activities provided approximately $21.4 million, primarily resulting from the maturities of marketable securities of approximately $21.4 million, partially offset by purchases of property and equipment of approximately $37 thousand.

Net Cash Provided by Financing Activities